Trial reportNutrients2025
Multistrain Probiotics Plus Vitamin D Improve Gut Barrier Function and Gut Microbiota Composition in Irritable Bowel Syndrome Without Constipation: Results from a Double-Blind, Randomized, Placebo-Controlled Trial.
Trial report in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric and visual analysis of gut microbiota research in functional bowel disorders from 2016 to 2025.Frontiers in medicine · 2026Pooled it
- Trial
- Vitamin D and Intestinal Diseases: Impact on Intestinal Immunity and Gut Barrier Function.Diseases (Basel, Switzerland) · 2026Review
- Review
- Probiotic-Mediated Vitamin D Supplementation Improves the Gut Microbiota and Vitamin D Receptor Composition in Obese Rats.Food science & nutrition · 2026Article
- Clinical Guidance and Practical Recommendations for Probiotic Use in Patients With Irritable Bowel Syndrome, Functional Constipation, andJournal of neurogastroenterology and motility · 2026Review
- Clinical guidance and practical recommendations for probiotic use in patients with irritable bowel syndrome, functional constipation, and Clostridioides difficile infection considering sex-based differences: a Korean translation.Ewha medical journal · 2026Article
- The bile acid-gut microbiota-vitamin D axis: new insights into biliary atresia.Frontiers in cellular and infection microbiology · 2026Review
- Unveiling the aging-immune axis in irritable bowel syndrome: a multi-omics and machine learning approach to biomarker discovery and validation.Frontiers in immunology · 2026Article
- Narrative review of celiac disease and sports: nutritional deficiency and strategies to optimise athlete health and performance.Current research in food science · 2026Review
- Global landscape analysis of clinical trials on gut microbiota modulation therapies for irritable bowel syndrome.Frontiers in medicine · 2026Review
- Preliminary Study on Circulating REG3α and Its Associations with Vitamin D Supplementation and Inflammatory Biomarkers in Adults with Overweight and Obesity.Current issues in molecular biology · 2025Article
- Vitamin D and the aging skin: insights into oxidative stress, inflammation, and barrier function.Immunity & ageing : I & A · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe disruption of the intestinal barrier and the imbalance of the gut microbiota (GM) seem to play a major role in the complex pathogenesis of irritable bowel syndrome (IBS). Specific microbial strains could improve the gut microenvironment, promoting anti-inflammatory pathways; similarly, vitamin D supplementation could play a role in enhancing the barrier integrity and modulating the immune response in the gut. This study aims to evaluate the efficacy of a new multistrain probiotic, combined with vitamin D, in improving gut barrier function in IBS without constipation.
methodsIn this phase IIb double-blind randomized placebo-controlled, parallel-group, multicenter, clinical trial, 35 patients were treated for 12 weeks with OttaBac
resultsMean zonulin values showed a significant progressive reduction in the active group (-10.2 ng/mL at week 12,
conclusionsProbiotic plus vitamin D could improve IBS-associated symptoms through gut microbiota modulation and gut barrier enhancement, with persistent benefits after treatment discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.